Vanda's tradipitant meets in Phase II for gastroparesis

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) said tradipitant met the primary endpoint in the Phase II VLY-686-2301 trial to treat idiopathic and diabetic gastroparesis. The company plans to meet with regulatory authorities in the near future to determine next steps for tradipitant in the indication.

The double-blind, U.S. trial enrolled 141 patients to receive placebo or twice-daily 85 mg oral tradipitant for four weeks. On the primary endpoint, tradipitant significantly improved nausea score as measured by patient daily diaries from baseline to week four vs. placebo (1.25 vs. 0.73 points, p=0.0099). Tradipitant also met the secondary endpoint of increasing the percentage of nausea-free days vs. placebo (28.8% vs. 15%, p=0.016)...